Pioglitazone (PGZ) is a hypoglycemic therapeutic drug used in the treatment of type 2 diabetes which increases cell sensitivity to insulin via selective stimulation of the nuclear receptor peroxisome proliferator-activator receptor gamma (PPARγ) [1,2]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.